San Diego, CA, November 6, 2011 – Stamford Bioprocess Technologies and Phage Pharmaceuticals recently signed a Letter of Intent to provide mutual access to the companies’ complementary technologies and expertise. While Stamford has extensive experience in the production of biologic therapeutic proteins from mammalian cell culture, Phage Pharmaceuticals owns the proprietary E. coli bacterial “Intelligent Protein” technology.
“Many of our clients look to decrease the cost of goods for the manufacture of their promising therapeutic proteins, and Phage’s technology will now allow us to provide this benefit to our clients when it’s seen as a good fit,” stated Qamar Zaidi, President of Stamford Bioprocess Technologies.
Jamie Oliver, CEO and President of Phage Pharmaceuticals said, “Our ‘Intelligent Protein’ platform allows the production of fully soluble, properly folded proteins which are released into the supernatant. This technology has led to improved yields, simplified downstream processing and in some cases improved activities. We believe there is a marked synergism between Phage and Stamford, and this would benefit our clients.”
Phage Pharmaceuticals, Inc. is a private biopharmaceutical company based in San Diego, California. Phage has a proprietary E. coli bacterial expression system for proteins which results in the production of properly folded therapeutic proteins, and has the capacity to produce biosimilar and novel proteins for R&D and clinical-scale lots. The Company’s proprietary manufacturing process results in lower production costs and is associated with fewer waste by-products and impurities compared with conventional methods used in the manufacture of similar therapeutics. The Company maintains open INDs with the U.S. FDA for clinical development of FGF-1 and human growth hormone (“hGH”), both of which have shown proof of clinical safety and demonstrated efficacy in humans. Its cGMP manufacturing facility has been issued a drug manufacturing license by the California Dept. of Public Health.
Stamford Bioprocess Technologies is a biologic contract development and production organization in Orange County, Southern California. Stamford specializes in recombinant protein production offering services in cell line development, product and process characterization, and development of manufacturing processes that are optimized for robust high titer production of high purity proteins from cell culture. Processes are developed with scale up, manufacturability, economics and regulatory requirements in mind. For more information, visit www.stamfordbio.com.